AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Comparative Efficacy and Safety of in vivo CRISPR Gene Editing Therapies versus PCSK9 Monoclonal Antibodies in Familial Hypercholesterolemia: A Systemic Review and Network Meta-Analysis

By MURUGAVEL D, CHILAKALA TV, Dhanasekaran SD et al.

Introduction: Familial hypercholesterolemia (FH) remains associated with substantial residual cardiovascular risk despite advances in lipid-lowering therapies. Emerging in vivo CRISPR gene-editing therapies offer the potential for durable, one-time LDL-C reduction by targeting genes such as PCSK9 and ANGPTL3. We performed a systematic review and network meta-analysis comparing their efficacy and safety with established PCSK9 monoclonal antibodies. Methods: A systematic search of PubMed, Embase, Scopus, Web of Science, and ClinicalTrials.gov was performed from database inception through June 2026. Studies evaluating in vivo CRISPR gene-editing therapies and PCSK9 monoclonal antibodies in familial hypercholesterolemia were included. A Bayesian random-effects network meta-analysis was conducted, and risk of bias was assessed using RoB 2.0 Results: A total of 12 studies involving 50,073 participants were included in the analysis. Among them, 29,614 (59.1%) were male and 20,459 (40.9%) were female, with a pooled mean age of 59.8 years. Baseline LDL-C ranged from 124-196 mg/dL, and most patients had heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. For the primary endpoint of LDL-C reduction, VERVE-102 ranked highest (SUCRA 94.6%) and demonstrated greater LDL-C lowering than placebo (MD –62.0%, 95% CI –72.4 to –51.6), followed by evolocumab (MD –60.1%, 95% CI –63.5 to –56.7) and alirocumab (MD –59.8%, 95% CI –63.1 to –56.4). For the secondary endpoint of major adverse cardiovascular events, PCSK9 monoclonal antibodies significantly reduced risk compared with placebo (RR 0.72, 95% CI 0.64-0.82). Serious adverse events were comparable across treatments (RR 1.03, 95% CI 0.94-1.13), while hepatotoxicity and infusion-related reactions remained uncommon (RR 1.18, 95% CI 0.82-1.69). Conclusion: In vivo CRISPR gene-editing therapies demonstrated LDL-C reductions comparable to or greater than established PCSK9 monoclonal antibodies, with VERVE-102 achieving the highest efficacy ranking. While long-term cardiovascular outcome data remain limited, emerging gene-editing platforms showed favorable safety profiles and durable lipid lowering. Overall risk of bias was low across included studies, supporting the robustness of these findings.

doi.org/10.1161/circ.154.suppl_1.16254Interventions

AgingResearch.News